Evaluation of serum chondroitin sulfate and hyaluronan: Biomarkers for osteoarthritis in canine hip dysplasia

Journal of Veterinary Science

Volumn 9, Issue 3, 2008, Pages 317-325

  Nganvongpanit, Korakot ^a   Itthiarbha, Akanit ^a   Ong Chai, Siriwan ^a   Kongtawelert, Prachya ^a  

^a CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

Biomarker; Chondroitin sulfate; Dog; Hip dysplasia; Osteoarthritis

Indexed keywords

CANIS FAMILIARIS;

EID: 50849101983     PISSN: 1229845X     EISSN: None     Source Type: Journal    
DOI: 10.4142/jvs.2008.9.3.317     Document Type: Article

References (63)

1. Allan G. Radiographic signs of joint disease. In: Thrall DE (ed.). Textbook of Veterinary Diagnostic Radiology. 2nd ed. pp. 130-150, Saunders, Philadelphia, 1994.
2. Alwan WH, Carter SD, Bennett D, Edwards GB. Glycosaminoglycans in horses with osteoarthritis. Equine Vet J 1991, 23, 44-47.
3. Antonas KN, Fraser JR, Muirden KD. Distribution of biologically labelled radioactive hyaluronic acid injected into joints. Ann Rheum Dis 1973, 32, 103-111.
4. Arican M, Carter SD, May C, Bennett D. Hyaluronan in canine arthropathies. J Comp Pathol 1994, 111, 185-195.
5. Belcher C, Yaqub R, Fawthrop F, Bayliss M, Doherty M. Synovial fluid chondroitin and keratan sulphate epitopes, glycosaminoglycans, and hyaluronan in arthritic and normal knees. Ann Rheum Dis 1997, 56, 299-307.
6. Björk J, Kleinau S, Tengblad A, Smedegård G. Elevated levels of serum hyaluronate and correlation with disease activity in experimental models of arthritis. Arthritis Rheum 1989, 32, 306-311.
7. Blom AB, van der Kraan PM, van den Berg WB. Cytokine targeting in osteoarthritis. Curr Drug Targets 2007, 8, 283- 292.
8. Bondeson J, Wainwright SD, Lauder S, Amos N, Hughes CE. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res Ther 2006, 8, R187.
9. Bruyere O, Collette JH, Ethgen O, Rovati LC, Giacovelli G, Henrotin YE, Seidel L, Reginster JY. Biochemical markers of bone and cartilage remodeling in prediction of longterm progression of knee osteoarthritis. J Rheumatol 2003, 30, 1043-1050.
10. Budsberg SC, Lenz ME, Thonar EJ. Serum and synovial fluid concentrations of keratan sulfate and hyaluronan in dogs with induced stifle joint osteoarthritis following cranial cruciate ligament transection. Am J Vet Res 2006, 67, 429-432.
11. Cardinet GH 3rd, Kass PH, Wallace LJ, Guffy MM. Association between pelvic muscle mass and canine hip dysplasia. J Am Vet Med Assoc 1997, 210, 1466-1473.
12. Caterson B, Flannery CR, Hughes CE, Little CB. Mechanisms involved in cartilage proteoglycan catabolism. Matrix Biol 2000, 19, 333-344.
13. Caterson B, Griffin J, Mahmoodian F, Sorrell JM. Monoclonal antibodies against chondroitin sulphate isomers: their use as probes for investigating proteoglycan metabolism. Biochem Soc Trans 1990, 18, 820-823.
14. Caterson B, Hughes CE, Roughley P, Mort JS. Anabolic and catabolic markers of proteoglycan metabolism in osteoarthritis. Acta Orthop Scand Suppl 1995, 266, 121-124.
15. Caterson B, Mahmoodian F, Sorrell JM, Hardingham TE, Bayliss MT, Carney SL, Ratcliffe A, Muir H. Modulation of native chondroitin sulphate structure in tissue development and in disease. J Cell Sci 1990, 97, 411-417.
16. DeAngelis PL. Hyaluronan synthases: fascinating glycosyltransferases from vertebrates, bacterial pathogens, and algal viruses. Cell Mol Life Sci 1999, 56, 670-682.
17. Fuller CJ, Barr AR, Sharif M, Dieppe PA. Cross-sectional comparison of synovial fluid biochemical markers in equine osteoarthritis and the correlation of these markers with articular cartilage damage. Osteoarthritis Cartilage 2001, 9, 49-55.
18. George J, Stern R. Serum hyaluronan and hyaluronidase: very early markers of toxic liver injury. Clin Chim Acta 2004, 348, 189-197.
19. Goldberg RL, Rubin AS. Serum hyaluronate as a marker for disease severity in the Lactobacillus casei model of arthritis in the rat. J Rheumatol 1989, 16, 92-96.
20. Hazell PK, Dent C, Fairclough JA, Bayliss MT, Hardingham T. Changes in glycosaminoglycan epitope levels in knee joint fluid following injury. Arthritis Rheum 1995, 38, 953-959.
21. Hegemann N, Kohn B, Brunnberg L, Schmidt MF. Biomarkers of joint tissue metabolism in canine osteoarthritic and arthritic joint disorders. Osteoarthritis Cartilage 2002, 10, 714-721.
22. Heinegård D, Hascall VC. Aggregation of cartilage proteoglycans. 3. Characteristics of the proteins isolated from trypsin digests of aggregates. J Biol Chem 1974, 249, 4250-4256.
23. Hollander AP, Heathfield TF, Webber C, Iwata Y, Bourne R, Rorabeck C, Poole AR. Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. J Clin Invest 1994, 93, 1722-1732.
24. Jacques C, Gosset M, Berenbaum F, Gabay C. The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation. Vitam Horm 2006, 74, 371-403.
25. Johnson JA, Austin C, Breur GJ. Incidence of canine appendicular musculoskeletal disorders in 16 veterinary teaching hospitals from 1980 through 1989. Vet Comp Orth Traum 1994, 7, 56-59.
26. Kaewsakorn T, Chotayaporn M, Suwankong N, Nganvongpanit K, Jitpean S, Cutesuwan P. Normal hematology and blood chemistry in small, medium and larged adult healthy dogs. Chiangmai Vet J 2003, 1, 35-49.
27. Kelly GS. The role of glucosamine sulfate and chondroitin sulfates in the treatment of degenerative joint disease. Altern Med Rev 1998, 3, 27-39.
28. Kiani C, Chen L, Wu YJ, Yee AJ, Yang BB. Structure and function of aggrecan. Cell Res 2002, 12, 19-32.
29. Kikuchi T, Yamada H, Shimmei M. Effect of high molecular weight hyaluronan on cartilage degeneration in a rabbit model of osteoarthritis. Osteoarthritis Cartilage 1996, 4, 99-110.
30. Knudson CB, Knudson W. Hyaluronan-binding proteins in development, tissue homeostasis, and disease. FASEB J 1993, 7, 1233-1241.
31. Knudson W. The role of CD44 as a cell surface hyaluronan receptor during tumor invasion of connective tissue. Front Biosci 1998, 1, d604-615.
32. Kongtawelert P, Ghosh P. An enzyme-linked immunosorbent-inhibition assay for quantiation of hyaluronan (hyaluronic acid) in biological fluids. Anal Biochem 1989, 178, 367-372.
33. Leighton EA. Genetics of canine hip dysplasia. J Am Vet Med Assoc 1997, 210, 1474-1479.
34. Leipold HR, Goldberg RL, Lust G. Canine serum keratan sulfate and hyaluronate concentrations. Relationship to age and osteoarthritis. Arthritis Rheum 1989, 32, 312-321.
35. Lohmander LS. Markers of cartilage metabolism in arthrosis. A review. Acta Orthop Scand 1991, 62, 623-632.
36. Lohmander LS, Dahlberg L, Eyre D, Lark M, Thonar EJ, Ryd L. Longitudinal and cross-sectional variability in markers of joint metabolism in patients with knee pain and articular cartilage abnormalities. Osteoarthritis Cartilage 1998, 6, 351-361.
37. Lohmander LS, Ionescu M, Jugessur H, Poole AR. Changes in joint cartilage aggrecan after knee injury and in osteoarthritis. Arthritis Rheum 1999, 42, 534-544.
38. Lust G. An overview of the pathogenesis of canine hip dysplasia. J Am Vet Med Assoc 1997, 210, 1443-1445.
39. Manicourt DH, Pita JC. Quantification and characterization of hyaluronic acid in different topographical areas of normal articular cartilage from dogs. Coll Relat Res 1988, 8, 39-47.
40. Masuhara K, Nakai T, Yamaguchi K, Yamasaki S, Sasaguri Y. Significant increases in serum and plasma concentrations of matrix metalloproteinases 3 and 9 in patients with rapidly destructive osteoarthritis of the hip. Arthritis Rheum 2002, 46, 2625-2631.
41. May SA. Degenerative joint disease (osteoartritis), osteoartrosis, secondary joint disease. In: Holton JEF, Collinson R (eds.). Manual of Small Animal Arthrology. pp. 62-74, Bristish Small Animal Veterinary Association Bournemounth, Cheltenham, 1994.
42. McLaughlin RM, Roush JK. Diagnosing osteoarthritis. Vet Med 2002, 97, 120-133.
43. Nganvongpanit K, Ong-Chai S. Biological marker for canine osteoarthritis diagnosis. Chiangmai Vet J 2004, 2, 39-49.
44. Okumura M, Tagami M, Fujinaga T. Measurement of serum and synovial fluid keratan sulphate and antibody to collagen type II in equine osteoarthritis. Zentralbl Veterinarmed A 1998, 45, 513-516.
45. Owens JM, Biery DN. Radiographic Interpretation for the Small Animal Clinician. 2nd ed. Williams & Wilkins, Baltimore, 1999.
46. Paimela L, Heiskanen A, Kurki P, Helve T, Leirisalo-Repo M. Serum hyaluronate level as a predictor of radiologic progression in early rheumatoid arthritis. Arthritis Rheum 1991, 34, 815-821.
47. Peansukmanee S, Trinarong C, Kongtawelert P, Ongchai S. Chondroitin sulfate epitopes in sera of normal and osteoarthritic horses. Chiangmai Vet J 2003, 1, 3-10.
48. Petersson IF, Boegård T, Svensson B, Heinegård D, Saxne T. Changes in cartilage and bone metabolism identified by serum markers in early osteoarthritis of the knee joint. Br J Rheumatol 1998, 37, 46-50.
49. Pothacharoen P, Siriaunkgul S, Ong-Chai S, Supabandhu J, Kumja P, Wanaphirak C, Sugahara K, Hardingham T, Kongtawelert P. Raised serum chondroitin sulfate epitope level in ovarian epithelial cancer. J Biochem 2006, 140, 517-524.
50. Pothacharoen P, Teekachunhatean S, Louthrenoo W, Yingsung W, Ong-Chai S, Hardingham T, Kongtawelert P. Raised chondroitin sulfate epitopes and hyaluronan in serum from rheumatoid arthritis and osteoarthritis patients. Osteoarthritis Cartilage 2006, 14, 299-301.
51. Ratcliffe A, Beauvais PJ, Saed-Nejad F. Differential levels of synovial fluid aggrecan aggregate components in experimental osteoarthritis and joint disuse. J Orthop Res 1994, 12, 464-473.
52. Ratcliffe A, Billingham MEJ, Saed-Nejad F, Muir H, Hardingham TE. Increased release of matrix components from articular cartilage in experimental canine osteoarthritis. J Orthop Res 1992, 10, 350-358.
53. Rettenmaier JL, Keller GG, Lattimer JC, Corley EA, Ellersieck MR. Prevalence of canine hip dysplasia in a veterinary teaching hospital population. Vet Radiol Ultrasound 2002, 43, 313-318.
54. Roush JK, McLaughlin RM, Radlinsky MAG. Understanding the pathophysiology of osteoarthritis. Vet Med 2002, 97, 108-119.
55. Sakugawa H, Nakayoshi T, Kobashigawa K, Yamashiro T, Maeshiro T, Miyagi S, Shiroma J, Toyama A, Nakayoshi T, Kinjo F, Saito A. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2005, 11, 255-259.
56. Simánek V, Kren V, Ulrichová J, Gallo J. The efficacy of glucosamine and chondroitin sulfate in the treatment of osteoarthritis: Are these saccharides drugs or nutraceuticals? Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2005, 149, 51-56.
57. Smedsrød B, Kjellén L, Pertoft H. Endocytosis and degradation of chondroitin sulphate by liver endothelial cells. Biochem J 1985, 229, 63-71.
58. Smedsrød B, Pertoft H, Gustafson S, Laurent TC. Scavenger functions of the liver endothelial cell. Biochem J 1990, 266, 313-327.
59. Smith GK, Mayhew PD, Kapatkin AS, Mckelvie PJ, Shofer FS, Gregor TP. Evaluation of risk factors for degenerative joint disease associated with hip dysplasia in German shepherd dogs, Golden retrievers, Labrador retrievers, and Rottweilers. J Am Vet Med Assoc 2001, 219, 1719-1724.
60. Tangkijvanich P, Kongtawelert P, Pothacharoen P, Mahachai V, Suwangool P, Poovorawan Y. Serum hyaluronan: a marker of liver fibrosis in patients with chronic liver disease. Asian Pac J Allergy Immunol 2003, 21, 115-120.
61. Uesaka S, Nakayama Y, Shirai Y, Yoshihara K. Serum and synovial fluid levels of chondroitin sulfate in patients with osteoarthritis of the knee joint. J Nippon Med Sch 2001, 68, 165-170.
62. Wight TN, Kinsella MG, Qwarnström EE. The role of proteoglycans in cell adhesion, migration and proliferation. Curr Opin Cell Biol 1992, 4, 793-801.
63. Worrall JG, Wilkinson LS, Bayliss MT, Edwards JC. Zonal distribution of chondroitin-4-sulphate/dermatan sulphate and chondroitin-6-sulphate in normal and diseased human synovium. Ann Rheum Dis 1994, 53, 35-38.